Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on development and discovery of novel treatments for cardiometabolic diseases and cancer, announced today that it’s been awarded a phase II Small Business Technology Transfer grant and a supplemental stage I grant, both from the National Cancers Institute of the National Institutes of Wellness pharmaciecambier.com/kamagra-oral-jelly.html . The phase II award of $1,066,916 supports research and advancement for the Company's tumor-activated prodrug platform for the treating a variety of cancers.